Pandemic Timeline

Researcher for Israel’s Ministry of Health finds that serious side effects are not rare, not transient

Serious side effects: not rare, not transient

The research team repeatedly stressed during the discussion that their findings indicate that, contrary to what has been thought and claimed so far, in many cases, serious adverse events are long-lasting.

Yaffa Shir-Raz, August 22, 2022

The research was based on a Naranjo questionnaire.  The Naranjo Algorithm is used to determine whether adverse drug reactions are directly related to a drug.  The research team determined that adverse reactions following the COVID-19 jabs were indeed related to the jabs.

During the discussion, the researchers explain an important point, which is critical to understanding the scope of the reports on the side effects identified in the study: it turns out that although all the HMOs in Israel were asked by the MOH to forward their reports on the side effects to the ministry, in practice, the bulk of the data came from only one small HMO – Meuchedet, while the rest of the HMOs, and especially Maccabi and Clalit – the two largest HMOs in Israel, did not cooperate.

Yaffa Shir-Raz, August 22, 2022

In other words, the large HMOs had been instructed to report adverse events to the government but failed to do so.  Project Veritas found that US medical providers were refusing to report as well.  The Emergency Use Authorizations had assumed that the medical providers would fulfill the role of researcher in the jab rollout; but for the most part, this did not happen.  Further compounding the reporting issues, reporting agency guidelines disregarded adverse events taking place within 14 days of administration.

Israel’s Minister of Health was warned of potential legal implications because the public had been told that serious side effects were rare and short-term.

The meeting took place sometime in early June.  The discussion contradicts a report later published by Israel’s Ministry of Health.

Sources:

See also, on this site:

Comments are closed.